TYR and chronic myelogenous leukemia, BCR-ABL1 positive: The first oncogene discovered as the direct etiological basis of a malignancy, the BCR/ABL1 translocation in chronic myeloid leukemia (CML), results in dysregulated tyrosinase activity, which can be treated using the tyrosine kinase inhibitor Imatinib [10,11].